CO6450649A2 - Formulaciones líquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazina - Google Patents

Formulaciones líquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazina

Info

Publication number
CO6450649A2
CO6450649A2 CO11143307A CO11143307A CO6450649A2 CO 6450649 A2 CO6450649 A2 CO 6450649A2 CO 11143307 A CO11143307 A CO 11143307A CO 11143307 A CO11143307 A CO 11143307A CO 6450649 A2 CO6450649 A2 CO 6450649A2
Authority
CO
Colombia
Prior art keywords
disorder
piperazine
sulfanil
penyl
dimethylphenyl
Prior art date
Application number
CO11143307A
Other languages
English (en)
Inventor
Svend Treppendahl
De Diego Heidi Lopez
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42669509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6450649(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of CO6450649A2 publication Critical patent/CO6450649A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Lubricants (AREA)

Abstract

Una formulación farmacéutica líquida que comprende una sal de 1-2-(2,4-dimetilfenilsulfaniI)fenil]piperazina la cual tiene la siguiente estructura moleculary un método para el tratamiento de una enfermedad seleccionada de trastornos del estado de ánimo; trastorno depresivo grave; trastorno de ansiedad generalizada; trastorno de pánico; trastorno de estrés post-traumático; depresión asociada con el deterioro cognitivo, enfermedad de Alzheimer o ansiedad; depresión con síntomas residuales; dolor crónico; trastorno de la alimentación o abuso, donde dicho método comprende la administración de una cantidad terapéuticamente efectiva de una formulación líquida de acuerdo con cualquiera de las reivindicaciones 1-5 a un paciente que lo necesita.
CO11143307A 2009-04-24 2011-10-24 Formulaciones líquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazina CO6450649A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21454009P 2009-04-24 2009-04-24
DKPA200900531 2009-04-24

Publications (1)

Publication Number Publication Date
CO6450649A2 true CO6450649A2 (es) 2012-05-31

Family

ID=42669509

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11143307A CO6450649A2 (es) 2009-04-24 2011-10-24 Formulaciones líquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazina

Country Status (35)

Country Link
US (4) US8940746B2 (es)
EP (1) EP2421534B1 (es)
JP (1) JP5722879B2 (es)
KR (1) KR101779214B1 (es)
CN (2) CN102405048A (es)
AR (2) AR076400A1 (es)
AU (1) AU2010238946B2 (es)
BR (1) BRPI1015338C1 (es)
CA (1) CA2759456C (es)
CL (1) CL2011002631A1 (es)
CO (1) CO6450649A2 (es)
CR (1) CR20110554A (es)
DK (1) DK2421534T3 (es)
DO (2) DOP2011000319A (es)
EA (1) EA021122B1 (es)
ES (1) ES2512719T3 (es)
GE (1) GEP20135938B (es)
HK (1) HK1206732A1 (es)
HR (1) HRP20140880T1 (es)
IL (1) IL215362A0 (es)
MA (1) MA33298B1 (es)
MX (1) MX2011011119A (es)
MY (1) MY155288A (es)
NZ (1) NZ596431A (es)
PL (1) PL2421534T3 (es)
PT (1) PT2421534E (es)
RS (1) RS53539B1 (es)
SG (1) SG175124A1 (es)
SI (1) SI2421534T1 (es)
SM (1) SMT201400159B (es)
TN (1) TN2011000504A1 (es)
TW (1) TWI461224B (es)
UA (1) UA106985C2 (es)
WO (1) WO2010121621A1 (es)
ZA (1) ZA201107731B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5722879B2 (ja) 2009-04-24 2015-05-27 ハー・ルンドベック・アクチエゼルスカベット １−［２−（２，４−ジメチルフェニルスルファニル）フェニル］ピペラジンの塩の液体製剤
US9499504B2 (en) 2012-09-19 2016-11-22 Sandoz Ag Crystalline form of vortioxetine hydrobromide
US9732053B2 (en) 2013-07-01 2017-08-15 Lek Pharmaceuticals D.D. 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form
EP3099669A1 (en) 2014-01-31 2016-12-07 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
GB201419261D0 (en) 2014-10-29 2014-12-10 Therakind Ltd Formulations
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
JO3456B1 (ar) * 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
CN108473451B (zh) 2016-02-08 2022-07-15 H.隆德贝克有限公司 1-[2-(2,4-二甲基-苯基硫烷基)-苯基]哌嗪的合成
JP2019524682A (ja) 2016-07-01 2019-09-05 ハー・ルンドベック・アクチエゼルスカベット 抗うつ作用の速い発現のためのボルチオキセチン投与計画
CN106518807A (zh) * 2016-09-17 2017-03-22 北京万全德众医药生物技术有限公司 乳酸沃替西汀晶型的制备方法
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN107011289A (zh) * 2017-03-10 2017-08-04 万全万特制药（厦门）有限公司 沃替西汀β晶型的制备方法
GB2564887A (en) * 2017-07-26 2019-01-30 Azad Pharmaceutical Ingredients Ag New route of synthesis to vortioxetine salts
WO2021198778A1 (en) 2020-04-03 2021-10-07 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine for prevention or treatment of emotional blunting

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
ATE406894T1 (de) 2003-04-04 2008-09-15 Lundbeck & Co As H 4-(2-phenylsulfanyl-phenyl)-piperidin-derivate als serotonin-wiederaufnahme-hemmer
WO2007144005A1 (en) 2006-06-16 2007-12-21 H. Lundbeck A/S 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
CA2656057C (en) * 2006-06-16 2012-10-02 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
TWI405588B (zh) * 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
JP5722879B2 (ja) 2009-04-24 2015-05-27 ハー・ルンドベック・アクチエゼルスカベット １−［２−（２，４−ジメチルフェニルスルファニル）フェニル］ピペラジンの塩の液体製剤

Also Published As

Publication number Publication date
US8940746B2 (en) 2015-01-27
KR20120022809A (ko) 2012-03-12
IL215362A0 (en) 2011-12-29
US10034876B2 (en) 2018-07-31
HRP20140880T1 (hr) 2014-11-07
MY155288A (en) 2015-09-30
BRPI1015338B1 (pt) 2021-01-05
US20150094316A1 (en) 2015-04-02
ES2512719T3 (es) 2014-10-24
JP2012524735A (ja) 2012-10-18
TWI461224B (zh) 2014-11-21
JP5722879B2 (ja) 2015-05-27
EA021122B1 (ru) 2015-04-30
US20170224677A1 (en) 2017-08-10
NZ596431A (en) 2012-12-21
CA2759456C (en) 2017-10-31
AU2010238946A1 (en) 2011-12-08
SG175124A1 (en) 2011-12-29
WO2010121621A1 (en) 2010-10-28
DOP2012000211A (es) 2013-03-31
AU2010238946B2 (en) 2013-03-28
CN104693145A (zh) 2015-06-10
AR122051A2 (es) 2022-08-10
BRPI1015338A2 (pt) 2016-05-31
RS53539B1 (en) 2015-02-27
AR076400A1 (es) 2011-06-08
SMT201400159B (it) 2015-01-15
MX2011011119A (es) 2011-11-04
GEP20135938B (en) 2013-10-10
CL2011002631A1 (es) 2012-04-09
ZA201107731B (en) 2013-02-27
TN2011000504A1 (en) 2013-05-24
CN102405048A (zh) 2012-04-04
EP2421534A1 (en) 2012-02-29
US20120035188A1 (en) 2012-02-09
US20190167667A1 (en) 2019-06-06
UA106985C2 (uk) 2014-11-10
US10857149B2 (en) 2020-12-08
DK2421534T3 (da) 2014-10-13
MA33298B1 (fr) 2012-05-02
EA201171287A1 (ru) 2012-04-30
PL2421534T3 (pl) 2014-12-31
SI2421534T1 (sl) 2014-11-28
TW201041604A (en) 2010-12-01
HK1206732A1 (en) 2016-01-15
US9475748B2 (en) 2016-10-25
PT2421534E (pt) 2014-10-29
CR20110554A (es) 2012-02-14
EP2421534B1 (en) 2014-09-03
KR101779214B1 (ko) 2017-09-18
CA2759456A1 (en) 2010-10-28
DOP2011000319A (es) 2012-02-29
BRPI1015338B8 (pt) 2021-05-25
BRPI1015338C1 (pt) 2021-08-10

Similar Documents

Publication Publication Date Title
CO6450649A2 (es) Formulaciones líquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazina
CL2008003363A1 (es) Uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina y sus sales farmaceuticamente aceptables para tratar depresion severa, ansiedad, abuso o dolor cronico, en pacientes que han recibido medicacion con anterioridad y que han abandonado o reducido a eventos adversos relacionados con el sueño o la actividad sexual.
ES2545959T3 (es) Un medicamento consistente en un derivado de carboestirilo y donepezilo para el tratamiento de la enfermedad de Alzheimer
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
CO6390109A2 (es) Inhibidores de syk de imidazopirazina
ECSP067019A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
CO6390078A2 (es) Inihibidores de syk de imidazopirazina
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
UY30477A1 (es) Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteina
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.
EA200802208A1 (ru) Применение флибансерина для лечения расстройств полового влечения в постклимактерический период
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
CO2022002638A2 (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen una mutación en el gen gla
ATE513562T1 (de) Nicht-spezifische immunstimulierende mittel
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
CL2015001615A1 (es) Una composicion farmaceutica que comprende vortioxetina y donepezilo junto con un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de disfuncion cognitiva, demencia en la enfermedad de alzheimer, disfuncion cognitiva asociada a la depresion y a la esquizofrenia, entre otras enfermedades.
UY30029A1 (es) Derivados de piperidina, sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones
CO6311083A2 (es) 4-((1r,3s)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina para el tratamiento de la disfunción cognitiva
ECSP077843A (es) Tratamiento o prevención del prurito
ECSP10010567A (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona
CL2011000805A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular.
AR065796A1 (es) Formulaciones liquidas de sales de 4-(2-(4-metilfenilsulfanil)fenil) piperidina

Legal Events

Date Code Title Description
FG Application granted